Respiratory Syncytial Virus Antigens and Antibodies

Respiratory syncytial virus (RSV) has a high mortality rate and is the leading cause of lower respiratory tract infections in children and infants worldwide. Scientists have been researching and developing therapies for RSV infections since the 1960s, but a safe vaccine remains elusive.

Download this whitepaper to learn more about the development of RSV:

• Vaccines
• Therapeutic drugs
• Immunodiagnostics